Hudson Value Partners LLC Has $341,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Hudson Value Partners LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 33.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,856 shares of the biopharmaceutical company’s stock after selling 5,978 shares during the quarter. Hudson Value Partners LLC’s holdings in Pfizer were worth $341,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in PFE. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. VisionPoint Advisory Group LLC lifted its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at about $36,000. DiNuzzo Private Wealth Inc. bought a new stake in Pfizer during the 4th quarter worth approximately $37,000. Finally, Life Planning Partners Inc purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $39,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Stock Performance

NYSE:PFE traded up $0.19 during trading hours on Friday, reaching $28.88. The stock had a trading volume of 22,589,127 shares, compared to its average volume of 44,974,800. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a 50 day simple moving average of $27.27 and a 200 day simple moving average of $27.94. The stock has a market cap of $163.65 billion, a P/E ratio of -481.33, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. Pfizer’s dividend payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.